PRESS RELEASE_US Hospital.pdf
U.S. Medical Center Selects Nexstim NBS 6 System for Clinical Mapping and Therapy Applications
Press Release, Helsinki, 11 November 2026 at 9 AM (EEST)
U.S. Medical Center Selects Nexstim NBS 6 System for Clinical Mapping and Therapy Applications
Nexstim Plc ("Nexstim" or "Company") announced that it has received a purchase order from a major U.S. medical center for a Nexstim NBS 6 system configured for both brain mapping and therapy applications. The customer is new to Nexstim nTMS technology and has purchased a system configuration that includes Nexstim's FDA-cleared motor mapping, speech mapping, and therapy modules.
They are looking to conduct brain mapping for both adult and pediatric patients. Nexstim nTMS is uniquely suited for pediatrics, because of the limited brain mapping options available for this population. With nTMS, motor mapping can be done entirely passively and has been done in children as young as 8 weeks of age. Children may be mapped while playing with toys, watching cartoons and sitting in their caregiver’s lap. nTMS captures functional areas that may have migrated due to lesion-induced functional reorganization, which can be dramatic in this population.1, 2
Nexstim nTMS language mapping is conducted in a child-friendly environment and has been performed on children as young as 4 years of age. Unlike invasive mapping directly on the brain's surface, nTMS can be performed bilaterally, capturing function that may have relocated to the opposite hemisphere, which is not uncommon in pediatrics.1, 3
Mikko Karvinen, CEO of Nexstim, commented:
"We are pleased to see continued interest in multifunctional NBS 6 systems that can support both diagnostic and therapeutic applications. This order reflects the growing demand among leading U.S. healthcare organizations for technologies that can be utilized across departments and patient populations while maintaining a high standard of accuracy and precision. We look forward to supporting this new center and welcoming them to the growing nTMS user community."
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS System 6 is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit https://www.nexstim.com/.
References
1. Narayana, S. et al. Clinical utility of transcranial magnetic stimulation in the presurgical evaluation of motor, speech and language functions in young children with refractory epilepsy or brain tumor: preliminary evidence. Front. Neurol. 12, 664782 (2021).
2. Raffa, G. et al. The role of navigated transcranial magnetic stimulation for surgery of motor‑eloquent brain tumors: a systematic review and meta‑analysis. Clin. Neurol. Neurosurg. 180, 47–53 (2019).
3. Pasichnik, A. et al. Discrepant expressive language lateralization in children and adolescents with epilepsy. Ann. Clin. Transl. Neurol. 9, 597–607 (2022).